A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (T-DXD) VERSUS TRASTUZUMAB EMTANSINE (T-DM1) IN SUBJECTS WITH HIGH-RISK HER2-POSITIVE PRIMARY BREAST CANCER WHO HAVE RESIDUAL INVASIVE DISEASE IN BREAST OR AXILLARY LYMPH NODES FOLLOWING NEOADJUVANT THERAPY (DESTINY BREAST05)¿
- Registry ID
- DS8201-A-U305
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- DAIICHI SANKYO INC
- Start date
- 2022-06-07
- Last update
- 2020-12-29
Conditions
- BREAST CANCER HER2-POSITIVE
Related clinical trials
- A TWO-PART, SEAMLESS, MULTICENTER, RANDOMIZED, OPEN-LABEL, ADAPTIVE PHASE II/III STUDY OF THE BLOOD-BRAIN BARRIER PENETRANT RO7771950 VERSUS TUCATINIB, BOTH IN COMBINATION WITH TRASTUZUMAB AND CAPECITABINE, IN PATIENTS WITH PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER, WITH OR WITHOUT CENTRAL NERVOUS SYSTEM METASTASES
- A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZANIDATAMAB IN COMBINATION WITH PHYSICIAN¿S CHOICE CHEMOTHERAPY COMPARED TO TRASTUZUMAB IN COMBINATION WITH PHYSICIAN'S CHOICE CHEMOTHERAPY FOR THE TREATMENT OF PARTICIPANTS WITH METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE PROGRESSED ON, OR ARE INTOLERANT TO, PREVIOUS TRASTUZUMAB DERUXTECAN TREATMENT
- A PHASE 1B/2 OPEN-LABEL STUDY OF DISITAMAB VEDOTIN MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS
- A PHASE 3, RANDOMIZED, MULTI-CENTER, OPEN-LABEL STUDY OF DB-1303 VERSUS
INVESTIGATOR¿S CHOICE CHEMOTHERAPY IN HUMAN EPIDERMAL GROWTH FACTOR
RECEPTOR 2 (HER2)-LOW, HORMONE RECEPTOR POSITIVE (HR+) METASTATIC BREAST
CANCER PATIENTS WHOSE DISEASE HAS PROGRESSED ON ENDOCRINE THERAPY (ET)
(DYNASTY-BREAST02)
- A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB IN COMBINATION WITH PHESGO® VERSUS PLACEBO IN COMBINATION WITH PHESGO® AS MAINTENANCE THERAPY AFTER FIRST LINE INDUCTION THERAPY IN PARTICIPANTS WITH PIK3CA-MUTATED HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
- DE-ESCALATION OF ADJUVANT CHEMOTHERAPY IN HER2-POSITIVE, ESTROGEN RECEPTOR-NEGATIVE, NODE-NEGATIVE EARLY BREAST CANCER PATIENTS WHO ACHIEVED PATHOLOGICAL COMPLETE RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY AND DUAL HER2 BLOCKADE-DECRESCENDO
View on source registry